Search

for
Search:

Sort by

Research

300-330 / 1000+ results

Safety, Tolerability, and Pharmacokinetics of CG2001 in Chinese Adult Male Subjects With Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multi-Dose, Phase 1 Clinical Study

research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study

January 2026

CG2001 is safe and well-tolerated for treating hair loss in men.

research Successful treatment of sebaceous adenitis in a rabbit with ciclosporin and triglycerides

13 citations , December 2008 in “Veterinary dermatology”

A rabbit with sebaceous adenitis was effectively treated with ciclosporin and medium-chain triglycerides.

Pharmacological Strategies for Mitigating Cytarabine-Induced Multi-Organ Toxicity: A Scoping Review on Mechanisms, Efficacy and Clinical Implications

research Pharmacological Strategies for Mitigating Cytarabine-Induced Multi-Organ Toxicity: A Scoping Review on Mechanisms, Efficacy and Clinical Implications

June 2026 in “Cancers”

Apraglutide and N-acetylcysteine (NAC) show promise in reducing cytarabine's harmful effects on organs.

research XEDAR activates the non-canonical NF-κB pathway

18 citations , August 2015 in “Biochemical and Biophysical Research Communications”

XEDAR triggers a specific signaling pathway in cells.

research Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome

39 citations , November 2015 in “Pediatric Nephrology”

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

research A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytesin vitroandin situ

66 citations , February 2013 in “PeerJ”

Activating cannabinoid receptor 1 reduces certain keratin levels, potentially aiding psoriasis treatment.

research Innovative Therapeutic Strategies in TYK2-Targeted Treatments: From Cancer to Autoimmune Disorders

1 citations , January 2024 in “ACS Medicinal Chemistry Letters”

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor

April 2024 in “JEADV clinical practice”

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

research Enzalutamide/finasteride/goserelin/zoledronic-acid

July 2024 in “Reactions Weekly”

research AB0163 ANTI-KU ANTIBODIES: MUCH MORE THAN SCLEROMYOSITIS

June 2020 in “Annals of the Rheumatic Diseases”

Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.

research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system

30 citations , January 2024 in “Frontiers in Pharmacology”

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

research One of the best treatments for alopecia areata remains unpublished

1 citations , June 2018 in “International Journal of Dermatology”

DNCB is highly effective for treating alopecia areata with minimal long-term side effects.

research 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata

1 citations , April 2017 in “Journal of Investigative Dermatology”

Abatacept may help some people with alopecia areata regrow hair.

research The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1

71 citations , May 2024 in “New England Journal of Medicine”

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report

1 citations , April 2023 in “Heliyon”

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers

3 citations , January 2011 in “Annals of Dermatology”

Blocking EGFR in skin cells doesn't majorly increase inflammation markers.

research Redefining hormone resistance in prostate cancer

38 citations , December 2009 in “Therapeutic Advances in Medical Oncology”

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.